

Nanexa receives "Notice of Allowance" for patent application in Canada

Nanexa AB (publ) today announced that the company has received a so-called "Notice of Allowance" for a patent application in Canada. The patent application refers to PharmaShell® administered in every conceivable way, for example by parenteral injection, inhalation or by oral administration.

"It is very gratifying to see that our continuous work with the patent portfolio is paying off, and a granted patent in Canada will further broaden our market for business. The patent process continues also in other countries and I foresee that we can receive further approvals of our patent applications this year," said David Westberg, CEO of Nanexa.

A Notice of Allowance announces that the patent application is considered ready for approval. However, the process is still ongoing, and it is currently not possible to predict when a patent will be granted.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.

Attachments

[Nanexa receives "Notice of Allowance" for patent application in Canada](#)